Llwytho...
Carfilzomib boosted combination therapy for relapsed multiple myeloma
Carfilzomib is a proteasome inhibitor that binds selectively and irreversibly to the 20S proteasome, the proteolytic core particle within the 26S proteasome, resulting in the accumulation of proteasome substrates and ultimately growth arrest and apoptosis of tumor cells. The development and ultimate...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Onco Targets Ther |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Dove Medical Press
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5317297/ https://ncbi.nlm.nih.gov/pubmed/28243125 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S102756 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|